Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens (Q38708817)

5 September 2017

1 reference

14 July 2021

Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens (English)

1 reference

5 September 2017

1 reference

1 reference

14 July 2021

Rashmi Dixit

1

1 reference

5 September 2017

Jenny Herz

series ordinal

2

1 reference

5 September 2017

Richard Dalton

series ordinal

3

1 reference

5 September 2017

Robert Booy

series ordinal

4

1 reference

5 September 2017

language of work or name

English

0 references

publication date

20 January 2016

1 reference

5 September 2017

24 February 2016

1 reference

14 July 2021

2 references

5 September 2017

14 July 2021

34

1 reference

5 September 2017

9

1 reference

5 September 2017

1152-1161

1 reference

Discovery and development of biopharmaceuticals: current issues

5 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Venoms, antivenoms and immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Antibody production: polyclonal-derived biotherapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Passive antibody therapy for infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Monoclonal antibodies in infectious diseases: clinical pipeline in 2011.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Report of a WHO workshop on the standardization and control of antivenoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Brief report: treatment of severe colchicine overdose with colchicine-specific Fab fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Acute plant poisoning and antitoxin antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Comparison between IgG and F(ab′)2 polyvalent antivenoms: neutralization of systemic effects induced by Bothrops asper venom in mice, extravasation to muscle tissue, and potential for induction of adverse reactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Immunoreactivity of a new generation of horse F(ab')2 preparations against European viper venoms and the tetanus toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Antivenoms for the treatment of snakebite envenomings: the road ahead

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Epidemiological, clinical and therapeutic aspects of Bothrops asper bites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites in Colombia: correlation between safety and biochemical characteristics of antivenoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Effect of preservatives on IgG aggregation, complement-activating effect and hypotensive activity of horse polyvalent antivenom used in snakebite envenomation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Assessment of the viral safety of antivenoms fractionated from equine plasma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Low pH formulation of whole IgG antivenom: Impact on quality, safety, neutralizing potency and viral inactivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Clinical safety of a polyvalent F(ab')2 equine antivenom in 223 African snake envenomations: a field trial in Cameroon. VAO (Venin Afrique de l'Ouest) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Comparison of F(ab')2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Modelling Tityus scorpion venom and antivenom pharmacokinetics. Evidence of active immunoglobulin G's F(ab')2 extrusion mechanism from blood to tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Pharmacokinetics of a F(ab')2 scorpion antivenom in healthy human volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Active immunity induced by passive IgG post-exposure protection against ricin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab')₂ fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

First clinical experiences with specific sheep Fab fragments in snake bite. Report of a multicentre study of Vipera berus envenoming.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

A comparison of ovine and equine antivenoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

First clinical experiences with a new ovine Fab Echis ocellatus snake bite antivenom in Nigeria: randomized comparative trial with Institute Pasteur Serum (Ipser) Africa antivenom.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Twentieth century toxinology and antivenom development in Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Snakebite envenoming from a global perspective: Towards an integrated approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Antivenom use, premedication and early adverse reactions in the management of snake bites in rural Papua New Guinea.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Neonatal Fc receptors discriminates and monitors the pathway of native and modified immunoglobulin G in placental endothelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Rabies post-exposure prophylaxis in the Philippines: health status of patients having received purified equine F(ab')(2) fragment rabies immunoglobulin (Favirab).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Rabies post-exposure prophylaxis with purified equine rabies immunoglobulin: one-year follow-up of patients with laboratory-confirmed category III rabies exposure in the Philippines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Safety of equine rabies immune globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Antivenin therapy in the emergency department

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Ability of polyvalent (Crotalidae) antivenin to neutralize myonecrosis, hemorrhage and lethality induced by timber rattlesnake (Crotalus horridus horridus) venom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Efficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without β-propiolactone, in the treatment of Bothrops asper bites in Colombia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Early infusion of a purified monospecific F(ab')2 antivenom serum for Bothrops lanceolatus bites in Martinique

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Clinical trial of an F(ab')2 polyvalent equine antivenom for African snake bites in Benin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

North American snake envenomation: diagnosis, treatment, and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

A large single-center experience with treatment of patients with crotalid envenomations: outcomes with and evolution of antivenin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Short-term outcomes after Fab antivenom therapy for severe crotaline snakebite

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Crotalidae polyvalent immune Fab: in patients with North American crotaline envenomation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Utilisation of Crotalidae polyvalent immune fab (ovine) for Viperidae envenomations in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Crotaline snake bite in the Ecuadorian Amazon: randomised double blind comparative trial of three South American polyspecific antivenoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

An open, randomized comparative trial of two antivenoms for the treatment of envenoming by Sri Lankan Russell's viper (Daboia russelii russelii).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Epidemiology of snakebites in Europe: a systematic review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Failure of antivenom to improve recovery in Australian snakebite coagulopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Clotting factor replacement and recovery from snake venom-induced consumptive coagulopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Efficacy of antivenom against the procoagulant effect of Australian brown snake (Pseudonaja sp.) venom: in vivo and in vitro studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Snake venom coagulopathy: use and abuse of blood products in the treatment of pit viper envenomation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Poisonous snakebite in central Texas. Possible indicators for antivenin treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Epidemiology and hospital course of rattlesnake envenomations cared for at a tertiary referral center in Central Arizona

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Complications of Crotalidae antivenin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Serum sickness following administration of Antivenin (Crotalidae) Polyvalent in 181 cases of presumed rattlesnake envenomation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Does the aggressive use of polyvalent antivenin for rattlesnake bites result in serious acute side effects?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Pediatric snakebites: lessons learned from 114 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Efficacy, safety, and use of snake antivenoms in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

A Randomized Multicenter Trial of Crotalinae Polyvalent Immune Fab (Ovine) Antivenom for the Treatment for Crotaline Snakebite in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Immediate and delayed allergic reactions to Crotalidae polyvalent immune Fab (ovine) antivenom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Initial postmarketing experience with crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Safety and cost-effectiveness of a clinical protocol implemented to standardize the use of Crotalidae polyvalent immune Fab antivenom at an academic medical center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Incidence of immediate hypersensitivity reaction and serum sickness following administration of Crotalidae polyvalent immune Fab antivenom: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Affinity-Purified, Mixed Monospecific Crotalid Antivenom Ovine Fab for the Treatment of Crotalid Venom Poisoning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Safety and efficacy of Crotalidae Polyvalent Immune Fab in pediatric crotaline envenomations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Acute hypersensitivity reactions associated with administration of crotalidae polyvalent immune Fab antivenom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Evaluation of antivenom therapy in Vipera palaestinae bites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Randomised controlled double-blind non-inferiority trial of two antivenoms for saw-scaled or carpet viper (Echis ocellatus) envenoming in Nigeria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Clinical effects and treatment of envenoming by Hoplocephalus spp. snakes in Australia: Australian Snakebite Project (ASP-12)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Tiger snake (Notechis spp) envenoming: Australian Snakebite Project (ASP-13).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Comparative study of the efficacy and safety of two polyvalent, caprylic acid fractionated [IgG and F(ab')2] antivenoms, in Bothrops asper bites in Colombia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

A randomised controlled trial of two infusion rates to decrease reactions to antivenom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Adder bites. A report of 68 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Clinical aspects of snake bite in the Pacific area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

[Snake bites in children: antivenom early reaction frequency in patients pretreated with histamine antagonists H1 and H2 and hydrocortisone]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Low incidence of early reactions to horse-derived F(ab')(2) antivenom for snakebites in Thailand.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Sixteen years of severe Tiger snake (Notechis) envenoming in Perth, Western Australia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Clinical study of tolerance and effectiveness of a F(ab')(2) polyvalent antienom for African snake bites in Kindia, Guinea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

European viper envenomings: Assessment of Viperfav™ and other symptomatic treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

A controlled clinical trial of a novel antivenom in patients envenomed by Bungarus multicinctus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Antivenom for critically ill children with neurotoxicity from scorpion stings.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Meta-analysis of controlled studies on immunotherapy in severe scorpion envenomation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Scorpion envenomations in young children in central Arizona

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Efficacy and safety of scorpion antivenom plus prazosin compared with prazosin alone for venomous scorpion (Mesobuthus tamulus) sting: randomised open label clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Effectiveness of anti scorpion venom for red scorpion envenomation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Treatment of the scorpion envenoming syndrome: 12-years experience with serotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Lack of scorpion antivenom leads to increased pediatric ICU admissions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Clinical presentation and treatment of black widow spider envenomation: a review of 163 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

A US perspective of symptomatic Latrodectus spp. envenomation and treatment: a National Poison Data System review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Examination of adverse events following black widow antivenom use in California

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

A randomized, double-blind, placebo-controlled trial of a highly purified equine F(ab)2 antibody black widow spider antivenom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Safety of i.v. administration of redback spider antivenom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Digoxin Immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Treatment with convalescent plasma for influenza A (H5N1) infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Specific polyclonal F(ab')2 neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Cross clade prophylactic and therapeutic efficacy of polyvalent equine immunoglobulin F(ab')2 against highly pathogenic avian influenza H5N1 in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013: epidemiological investigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Probable person-to-person transmission of avian influenza A (H5N1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Human infection with avian influenza A H6N1 virus: an epidemiological analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Emergence in China of human disease due to avian influenza A(H10N8)--cause for concern?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Prevention and treatment of influenza with hyperimmune bovine colostrum antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Modulation of innate immune responses by influenza-specific ovine polyclonal antibodies used for prophylaxis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Tracking the transmission and evolution of MERS-CoV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Nipah virus: vaccination and passive protection studies in a hamster model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Inhibition of infection caused by severe acute respiratory syndrome-associated coronavirus by equine neutralizing antibody in aged mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Inhibition of severe acute respiratory syndrome-associated coronavirus infection by equine neutralizing antibody in golden Syrian hamsters.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Protection from infection with severe acute respiratory syndrome coronavirus in a Chinese hamster model by equine neutralizing F(ab')2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Short report: treatment of snake envenomations by a new polyvalent antivenom composed of highly purified F(ab)2: results of a clinical trial in northern Cameroon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

Current use of Australian snake antivenoms and frequency of immediate-type hypersensitivity reactions and anaphylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

7 January 2021

An epidemiological and clinical study of snake-bites in childhood

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

7 January 2021

Prediction, prevention, and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

7 January 2021

Clinical effects of red-bellied black snake (Pseudechis porphyriacus) envenoming and correlation with venom concentrations: Australian Snakebite Project (ASP-11).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

7 January 2021

High rate of immediate systemic hypersensitivity reactions to tiger snake antivenom

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

7 January 2021

Funnel-web spider bite: a systematic review of recorded clinical cases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

7 January 2021

Evaluation of anti-influenza efficiency of polyclonal IgG antibodies specific to the ectodomain of M2 protein of influenza A virus by passive immunization of mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.01.016

7 January 2021

Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic

1 reference

12 December 2020

Post-exposure treatment of Ebola virus using passive immunotherapy: proposal for a new strategy

1 reference

12 December 2020

A century of antivenom

1 reference

12 December 2020

Purified equine rabies immune globulin: a safe and affordable alternative to human rabies immune globulin

1 reference

12 December 2020

Development and study of the properties of immunoglobulin against Ebola fever

1 reference

12 December 2020

Successful treatment of avian influenza with convalescent plasma

1 reference

12 December 2020

Updated information on the epidemiology of Middle East respiratory syndrome coronavirus (MERS-CoV) infection and guidance for the public, clinicians, and public health authorities, 2012-2013.

1 reference

12 December 2020

Post-exposure prophylaxis for rabies with ERIG and IDRV in children

1 reference

12 December 2020

Interventions for preventing reactions to snake antivenom

1 reference

12 December 2020

Anaphylaxis and anaphylactoid reactions

1 reference

12 December 2020

Immunoreactivity and pharmacokinetics of horse anti-scorpion venom F(ab')2-scorpion venom interactions

1 reference

12 December 2020

A modification of Jerne's theory of antibody production using the concept of clonal selection

1 reference

12 December 2020

Severe snakebites in northern KwaZulu-Natal: treatment modalities and outcomes

1 reference

12 December 2020

Compared protective effect of nasal immunoprophylaxis using a new human monoclonal IgM antibody, human polyclonal antibodies, F(ab')2, amantadine, and zanamivir for prophylaxis of influenza A virus pneumonia in mice.

1 reference

12 December 2020

Efficacy of species specific anti-scorpion venom serum (AScVS) against severe, serious scorpion stings (Mesobuthus tamulus concanesis Pocock)--an experience from rural hospital in western Maharashtra.

1 reference

12 December 2020

[Evaluation of intravenous immunotherapy with purified F(ab')2 fragments (Viperfav)]

1 reference

12 December 2020

Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses

1 reference

12 December 2020

Estimating Potential Incidence of MERS-CoV Associated with Hajj Pilgrims to Saudi Arabia, 2014

1 reference

12 December 2020

Crotaline Fab antivenom appears to be effective in cases of severe North American pit viper envenomation: an integrative review

1 reference

12 December 2020

Effect of antivenom on venom pharmacokinetics in experimentally envenomed rabbits: toward an optimization of antivenom therapy

1 reference

12 December 2020

The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever

1 reference

12 December 2020

10.1016/J.VACCINE.2016.01.016

Identifiers

DOI

1 reference

5 September 2017

0 references

1 reference